BMS Gets US Approval Of Ozanimod For Relapsing MS, But Launch Delayed
Zeposia, one of three Celgene candidates central to last year’s merger with BMS, obtains US FDA approval in relapsing MS. BMS, however, will delay the launch due to the COVID-19 pandemic.
You may also be interested in...
Bristol Myers Squibb reported detailed results from the Phase III TRUE NORTH study that show durable remissions in a patient population that switches therapies due to loss of response.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.
After delaying the launch of the MS treatment due to the pandemic, Bristol now says the market is ready for a new launch. Immunology US business unit head Tina Deignan talked to Scrip about it.